Adam S. Kibel, MD, presented “Management of Localized High-Risk Prostate Cancer” during the Jackson Hole Seminars on January 30, 2019 in Jackson Hole, Wyoming.
How to cite: Kibel, Adam S. “Management of Localized High-Risk Prostate Cancer” January 30, 2019. Accessed [date today]. https://grandroundsinurology.com/management-of-localized-high-risk-prostate-cancer/
Management of Localized High-Risk Prostate Cancer – Summary:
Adam S. Kibel, MD, argues that aggressive curative therapy is the best practice for the management of high-risk prostate cancer. He observes that local therapies like surgery, along with combination therapies like external beam radiation therapy plus brachytherapy and androgen deprivation therapy, have shown themselves to be effective for improving overall survival.
About the Ralph E. Hopkins Urology Seminar
The Ralph E. Hopkins Urology Seminar, or Jackson Hole Seminars (JHS), is a multi-day conference that focuses on patient safety and cutting-edge updates in the assessment, diagnosis, and treatment of urologic conditions. The topics discussed include urologic cancers, stone disease, urologic reconstruction, female urology, infertility, emerging surgical techniques, and general urology. In addition to didactic expert lectures, this conference features unique interactive critique panel. Dr. Kibel presented this lecture during the 39th Annual JHS. Please visit this page in order to register for future JHS meetings.
ABOUT THE AUTHOR
Adam S. Kibel, MD, is the DiNovi Family Distinguished Chair of Urology at Brigham and Women’s Hospital and Dana-Farber Brigham and Women’s Cancer Center in Boston, Massachusetts. Dr. Kibel is also the Elliott Carr Cutler Professor of Surgery at Harvard Medical School, and Chairman of the Harvard Urology Residency Program. His clinical interests include genetics of prostate cancer, minimally-invasive surgical treatments for urologic cancers, and robotic surgery for urologic cancers.
Dr. Kibel received his undergraduate and medical degrees from Cornell University Medical School. Dr. Kibel completed his urology residency at the Harvard Urology Program and his fellowship at the Brady Urologic Institute at John Hopkins.
Dr. Kibel has been listed as one of America’s Top Doctors by Castle Connolly and was named a top urologist by Boston magazine for his work on minimally invasive treatments for urologic cancers. Dr. Kibel has authored over 250 peer-reviewed publications on his research, with topics including the identification of molecular markers of urologic tumors, adjuvant and neoadjuvant approaches to treatment of aggressive disease and improved imaging of patients with urologic malignancies. Dr. Kibel’s research has been supported by the National Cancer Institute, American Cancer Society, American College of Surgeons, and the American Foundation for Urologic Disease.
